Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

By A. Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim, P. Das, M. R. Sarker, P. Daru, H. Rieder. American Journal of Respiratory and Critical Care Medicine, 2010

636 citations recorded by the source corpus.

Subfields: Infectious Diseases, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/e6eb2d82a7fb4c7fc24379f6d6c68bd7e63abd0d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Seung
2. H. Getahun
3. S. Keshavjee
4. M. Rich
5. G. Migliori
6. D. Falzon
7. S. Rüsch-Gerdes
8. M. Bauer

Citations in the corpus

• WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update (2011, methodology): “While shorter regimens would confer clear benefits and be preferred, evidence for the effectiveness of a 9-month regimen for MDR-TB patients has up to now been limited to data from one setting (included in this review)(22).”
• Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. (2015, background): “One study showed that a 9-mo treatment regimen was sufficient to affect cure in a small cohort of patients in Bangladesh (Van Deun et al. 2010).”